Search - tctmd.com

Displaying 41 - 60 of 536

Sort: Relevancy | Date

Presentation TCT 2024

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

Todd Neale

August 23, 2024

News Daily News

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Michael O'Riordan

August 02, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Michael O'Riordan

June 28, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

Hypertension Expert George Bakris Mourned by Colleagues and Friends

L.A. McKeown

June 18, 2024

News Daily News

Kidney Events High in Older Patients After HF Hospitalization

L.A. McKeown

May 30, 2024

News Daily News

FLOW: Semaglutide Scores Big in Diabetic Patients With CKD

L.A. McKeown

May 24, 2024

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News SCAI 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

L.A. McKeown

May 02, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Advertisement

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

September 2024 Dispatch for the CV Team

Scientific Statement Reviews Current Antithrombotic Options in PAD

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

August 2024 Dispatch for the CV Team

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Hypertension Expert George Bakris Mourned by Colleagues and Friends

Kidney Events High in Older Patients After HF Hospitalization

FLOW: Semaglutide Scores Big in Diabetic Patients With CKD

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content